Weight Loss During Treatment of Hepatitis C in HIV

描述（由申请人提供）：丙型肝炎病毒（HCV）现在是合并感染人类免疫缺陷病毒（HIV）的患者最常见的死亡原因。在美国，三分之一的hiv感染者同时感染了HCV。HIV/HCV合并感染与肝纤维化、肝硬化和肝功能衰竭的快速进展有关。因此，HCV治疗对于HIV/HCV合并感染患者的长期生存至关重要。然而，据报道，-70%的HIV/HCV患者在HCV治疗期间出现严重的体重减轻，这可能导致过早停止或修改HCV治疗。由于这种不良反应可以阻止晚期肝病高危患者接受最佳治疗，因此需要确定接受HIV/HCV双重治疗的HIV/HCV患者的体重减轻发生率和程度。研究还阐明了减肥的危险因素，可以加强对减肥背后的生物学机制的理解。本回顾性队列研究旨在检查双重治疗的HIV/HCV患者体重减轻的发生率，1)接受HCV治疗的单HCV感染患者和2)仅接受HIV治疗的单HIV感染者。减肥的风险因素也将被检查。本流行病学研究的结果可能最终有助于优化HIV/HCV患者的HCV治疗，并为评估体重减轻时身体组成和代谢异常的变化提供基础。

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is now the most common cause of death in patients coinfected with the human immunodeficiency virus (HIV). In the U.S., 1/3 of all HIV-infected patients are coinfected with HCV. HIV/HCV coinfection has been associated with rapid progression of liver fibrosis, cirrhosis, and hepatic failure. Thus, HCV therapy is critical for long-term survival of HIV/HCV-coinfected patients. However, -70% of HIV/HCV patients have been reported to develop severe weight loss during treatment of HCV, and this can result in premature cessation or modification of HCV therapy. Since this adverse effect can prevent patients at high- risk of advanced liver disease from receiving optimal therapy, determination of the incidence and degree of weight loss among HIV/HCV patients receiving dual HIV/HCV therapy is needed. Studies that also elucidate risk factors for weight loss can enhance understanding of biological mechanisms behind it. This retrospective cohort study seeks to examine the incidence of weight loss in dually treated HIV/HCV patients compared to 1) HCV-monoinfected patients who receive HCV therapy and 2) HIV-monoinfected individuals receiving only HIV therapy. Risk factors for weight loss will also be examined. The results of this epidemiological study may ultimately help to allow optimal treatment of HCV in HIV/HCV patients and provide the foundation to evaluate changes in body composition and metabolic abnormalities accompanying weight loss.